home / stock / innt / innt news

INNT News and Press, Innovate Biopharmaceuticals Inc.

Stock Information
Company Name: Innovate Biopharmaceuticals Inc.
Stock Symbol: INNT
Market: NASDAQ
Website: innovatebiopharma.com
Menu
INNT INNT Quote INNT Short INNT News INNT Articles INNT Message Board
Get INNT Alerts

News, Short Squeeze, Breakout and More Instantly...
INNT - 9 Meters Biopharma, a Rare, Orphan and Unmet Needs GI-Focused Company, is Created with the Transformative Merger Between Innovate Biopharmaceuticals and RDD Pharma

Completes concurrent financing of ~$22 million led by Orbimed Advisors, LLC Lead program, a proprietary long-acting GLP-1 receptor agonist, starting Phase 2 trial for Short Bowel Syndrome (SBS), an underserved, orphan condition Continued Phase 3 trial of larazotide; first and on...
INNT - Innovate Biopharmaceuticals Announces Full Year 2019 Financial Results And Strategic And Operational Updates

RALEIGH, NC / ACCESSWIRE / March 20, 2020 / Innovate Biopharmaceuticals, Inc. (the "Company" or "Innovate") (NASDAQ:INNT), a clinical stage biotechnology company focused on developing novel autoimmune and inflammation therapeutics, announced that it has filed its 2019 Annual Report on Form...

INNT - Innovate Biopharmaceuticals Affirms Timeline for Closing of Merger with RDD Pharma Ltd. Closing Expected Around the End of the First Quarter of 2020

Israeli Regulatory Approvals Appear on Track for Late March 2020 to Allow Closing of the Merger RALEIGH, NC / ACCESSWIRE / March 11, 2020 / Innovate Biopharmaceuticals, Inc. (NASDAQ:INNT), a clinical-stage biotechnology company focused on developing novel therapeutics for autoimmune a...

INNT - Innovate Biopharmaceuticals Announces Acceptance of Three Abstracts for the 2020 Digestive Disease Week (DDW) Conference

Highlighting Larazotide's Effect across the Gut-Vascular Barrier - a Fundamental Disease Mechanism in a Variety of Autoimmune and Inflammatory Diseases RALEIGH, NC / ACCESSWIRE / February 19, 2020 / Innovate Biopharmaceuticals, Inc. (NASDAQ:INNT), a clinical-stage...
INNT - Innovate Biopharmaceuticals Announces Shareholder Approval of All Proposals in Connection with the Pending Merger with RDD Pharma Ltd. to Create 9 Meters Biopharma, a GI-focused Platform Company

Closing of this transformative transaction expected in early Q2 2020 upon completion of remaining closing conditions and receipt of regulatory approval in Israel RALEIGH, NC / ACCESSWIRE / February 18, 2020 / Innovate Biopharmaceuticals, Inc. (Nasdaq: INNT - "Innovate"), a clinical stag...

INNT - RDD Pharma Enters into Non-Binding Letter of Intent to Acquire Naia Rare Diseases, Strengthening Gastroenterology Orphan Disease Pipeline

TEL AVIV, Israel and RICHMOND, Calif. , Nov. 13, 2019 /PRNewswire/ -- RDD Pharma, Ltd. ("RDD"), a company focused on orphan and innovative therapies for gastrointestinal disorders entered into a non-binding letter of intent ("LOI") to acquire Naia Rare Diseases ("Naia"), a biopharm...

INNT - SPWR, FRO among premarket gainers

Pfenex (NYSEMKT: PFNX ) +13%  as FDA OKs Pfenex Forteo biosimilar. More news on: Pfenex Inc., Mereo BioPharma Group plc, Livongo Health, Inc., Stocks on the move, Read more ...

INNT - Innovate Biopharmaceuticals to Merge with RDD Pharma Creating New Gastroenterology Company Focused on Specialty, Rare and Orphan Diseases

Deep Clinical-Stage Pipeline Combined With World-Class Leadership Team OrbiMed Advisors LLC to Lead a Concurrent Capital Raise 9 Meters Biopharma, Inc. Will Be the New Name of the Combined NASDAQ-Listed Public Company Conference Call on October 7, 2019 at 8:00 a.m. EDT / 5:0...

INNT - Innovate Biopharmaceuticals, Inc. Announces First Patient Dosed in the First Phase 3 Clinical Trial for Patients with Celiac Disease

CeD LA 3001 trial doses first patient in historic Phase 3 celiac disease trial RALEIGH, N.C., Aug. 13, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (“Innovate”) (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel therapeutics fo...

INNT - Innovate Biopharmaceuticals EPS in-line

Innovate Biopharmaceuticals (NASDAQ: INNT ): Q2 GAAP EPS of -$0.13 in-line. More news on: Innovate Biopharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Next 10